View Older Stories View More Recent Stories

Mar 26, 2021 01:00PM OSE Immunotherapeutics Reports 2020 Financial Results and Provides Business Update
Mar 26, 2021 01:00PM OSE Immunotherapeutics Reports 2020 Financial Results and Provides Business Update
Mar 15, 2021 02:30AM OSE Immunotherapeutics and ARCAGY - GINECO Announce Initiation of a Randomized Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer
Mar 15, 2021 01:30AM OSE Immunotherapeutics and ARCAGY - GINECO Announce Initiation of a Randomized Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer
Mar 11, 2021 12:00PM OSE Immunotherapeutics to Present New Data Reflecting Expansion and Progress on its Immuno-Oncology and Inflammation Preclinical Portfolio at the 2021 AACR Annual meeting
Mar 11, 2021 12:00PM OSE Immunotherapeutics to Present New Data Reflecting Expansion and Progress on its Immuno-Oncology and Inflammation Preclinical Portfolio at the 2021 AACR Annual Meeting
Feb 23, 2021 12:00PM OSE Immunotherapeutics Presentation at H.C. Wainwright Global Life Sciences Conference
Feb 23, 2021 12:00PM OSE Immunotherapeutics Presentation at H.C. Wainwright Global Life Sciences Conference
Feb 17, 2021 12:00PM OSE Immunotherapeutics Announces Granting of First European Patent Protecting Anti-IL-7 Receptor Antagonist OSE-127/S95011
Feb 17, 2021 12:00PM OSE Immunotherapeutics Announces Granting of First European Patent Protecting Anti-IL-7 Receptor Antagonist OSE-127/S95011
Feb 15, 2021 01:30AM OSE Immunotherapeutics Enters a Loan Agreement of up to €25 Million with the European Investment Bank
Feb 15, 2021 01:30AM OSE Immunotherapeutics Enters a Loan Agreement of up to €25 Million with the European Investment Bank
Jan 28, 2021 12:00PM OSE Immunotherapeutics Expands its Collaboration with MAbSilico to Use Artificial Intelligence to Accelerate Drug Development of Novel Antibody Therapeutics
Jan 28, 2021 12:00PM OSE Immunotherapeutics Expands its Collaboration with MAbSilico to Use Artificial Intelligence to Accelerate Drug Development of Novel Antibody Therapeutics
Jan 25, 2021 01:30AM OSE Immunotherapeutics Receives €1.3 Million Milestone Payment from Bpifrance for OSE-127/S95011
Jan 25, 2021 01:30AM OSE Immunotherapeutics Receives €1.3 Million Milestone Payment from Bpifrance for OSE-127/S95011
Jan 5, 2021 12:00PM OSE Immunotherapeutics Presentation at H.C. Wainwright BIOCONNECT 2021 Virtual Conference
Jan 5, 2021 12:00PM OSE Immunotherapeutics Presentation at H.C. Wainwright BIOCONNECT 2021 Virtual Conference
Dec 21, 2020 12:00PM OSE Immunotherapeutics Announces Enrolment of First Patient with Ulcerative Colitis in Phase 2 Trial Testing Anti-IL-7 Receptor Antagonist OSE-127/S95011
Dec 21, 2020 12:00PM OSE Immunotherapeutics Announces Enrolment of First Patient with Ulcerative Colitis in Phase 2 Trial Testing Anti-IL-7 Receptor Antagonist OSE-127/S95011
Dec 18, 2020 01:30AM OSE Immunotherapeutics Receives €5.2 M in Public Funding for the Clinical Development of CoVepiT, its Second Generation COVID-19 Vaccine
Dec 18, 2020 01:30AM OSE Immunotherapeutics Receives €5.2 M in Public Funding for the Clinical Development of CoVepiT, Its Second Generation COVID-19 Vaccine
Dec 3, 2020 12:00PM OSE Immunotherapeutics and Nantes University Hospital Announce Initiation of a Phase 1/2 Clinical Trial to Evaluate CD28 Antagonist FR104 in Patients Undergoing Renal Transplantation
Dec 3, 2020 12:00PM OSE Immunotherapeutics and Nantes University Hospital Announce Initiation of a Phase 1/2 Clinical Trial to Evaluate CD28 Antagonist FR104 in Patients Undergoing Renal Transplantation
Nov 9, 2020 12:00PM OSE Immunotherapeutics to Present at SITC Annual Meeting and at Additional International Immuno-Oncology Summits
Nov 9, 2020 12:00PM OSE Immunotherapeutics to Present at SITC Annual Meeting and at Additional International Immuno-Oncology Summits
Nov 5, 2020 12:00PM OSE Immunotherapeutics Provides COVID-19 Vaccine Update on CoVepiT, its Multi-Target and Long-Lasting Vaccine Candidate
Nov 5, 2020 12:00PM OSE Immunotherapeutics Provides COVID-19 Vaccine Update on CoVepiT, its Multi-Target and Long-Lasting Vaccine Candidate
Oct 30, 2020 02:30AM OSE Immunotherapeutics Presents OSE-230 as a Novel Agonist Monoclonal Antibody Therapy Triggering Resolution of Chronic Inflammation
Oct 30, 2020 02:30AM OSE Immunotherapeutics Presents OSE-230 as a Novel Agonist Monoclonal Antibody Therapy Triggering Resolution of Chronic Inflammation
Oct 22, 2020 12:00PM OSE Immunotherapeutics Announces Publication Supporting Additional New Mechanism of Action for Selective Antibody Antagonist of SIRPα BI 765063 in the Journal of Clinical Investigation
Oct 22, 2020 12:00PM OSE Immunotherapeutics Announces Publication Supporting Additional New Mechanism of Action for Selective Antibody Antagonist of SIRPα BI 765063 in the Journal of Clinical Investigation
Oct 12, 2020 12:00PM OSE Immunotherapeutics Receives European Patent Notice of Allowance For First-in-Class CD28-Antagonist Immunotherapy FR104
Oct 12, 2020 12:00PM OSE Immunotherapeutics Receives European Patent Notice of Allowance for First-in-Class CD28-Antagonist Immunotherapy FR104
Sep 21, 2020 01:30AM OSE Immunotherapeutics Presents Positive Step-1 Phase 3 Results for Tedopi® in NSCLC at the European Society for Medical Oncology Virtual Congress 2020
Sep 21, 2020 01:30AM OSE Immunotherapeutics Presents Positive Step-1 Phase 3 Results for Tedopi® in NSCLC at the European Society for Medical Oncology Virtual Congress 2020
Sep 17, 2020 12:00PM OSE Immunotherapeutics Reports First Half 2020 Results and Corporate Update
Sep 17, 2020 12:00PM OSE Immunotherapeutics Reports First Half 2020 Results and Corporate Update
Sep 8, 2020 01:30AM OSE Immunotherapeutics to Present at The H.C. Wainwright 22nd Annual Global Investment Conference
Sep 8, 2020 01:30AM OSE Immunotherapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference September 14 - 16, 2020 (Virtual Conference)
Aug 17, 2020 01:30AM OSE Immunotherapeutics Publishes Positive Preclinical COVID-19 Vaccine Results With Multi-Target Vaccine CoVepiT
Aug 17, 2020 01:30AM OSE Immunotherapeutics Publishes Positive Preclinical COVID-19 Vaccine Results With Multi-Target Vaccine CoVepiT
Jul 28, 2020 12:00PM OSE Immunotherapeutics To Present Step-1 Results of Phase 3 Clinical Trial of Tedopi® ‘Atalante 1’ in Non-Small Cell Lung Cancer at the European Society for Medical Oncology (ESMO) Virtual Congre
Jul 28, 2020 12:00PM OSE Immunotherapeutics To Present Step-1 Results of Phase 3 Clinical Trial of Tedopi® ‘Atalante 1’ in Non-Small Cell Lung Cancer at the European Society for Medical Oncology (ESMO) Virtual Congr
Jul 16, 2020 01:30AM OSE Immunotherapeutics Receives €200,000 from Nantes Metropole to Develop CoVepiT, its COVID-19 Prophylactic Vaccine Program
Jul 16, 2020 01:30AM OSE Immunotherapeutics Receives €200,000 from Nantes Metropole to Develop CoVepiT, its COVID-19 Prophylactic Vaccine Program
Jun 16, 2020 12:00PM OSE Immunotherapeutics Announces Results of 2020 Virtual Combined General Meeting
Jun 16, 2020 12:00PM OSE Immunotherapeutics Announces Results of 2020 Virtual Combined General Meeting
Jun 10, 2020 12:00PM OSE Immunotherapeutics Presents New Data Supporting Bispecific Antibody Checkpoint Inhibitor Platform (BiCKI®) and Bifunctional Therapy Targeting PD-1 and IL-7 (BiCKI®-IL-7) For Cancer Immunotherapy
Jun 10, 2020 12:00PM OSE Immunotherapeutics Presents New Data Supporting Bispecific Antibody Checkpoint Inhibitor Platform (BiCKI®) and Bifunctional Therapy Targeting PD-1 and IL-7 (BiCKI®-IL-7) For Cancer Immunotherapy
View More Recent Stories View Older Stories